Compare

Ensysce Biosciences, Inc. vs Cerenome, Inc. vs ProPhase Labs, Inc. vs China Pharma Holdings, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearEnsysce Biosciences, Inc.
ENSC
Cerenome, Inc.
CNSY
ProPhase Labs, Inc.
PRPH
China Pharma Holdings, Inc.
CPHI
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$5.07M$5.21M$4.34M$4.14M
Revenue growth (YoY)-2.8%-10.5%-35.8%-8.5%
Gross marginn/an/a31.9%-3.2%
Operating margin-202.1%-293.5%-415.4%-78.2%
Net margin-200.8%-429.4%-339.3%-76.9%
Net income-$10.18M-$22.39M-$14.74M-$3.19M
EPS (Diluted)-$3.98-$0.29-$1.74-$0.74
Operating cash flow-$7.81M-$20.77M-$8.34M$148.3K
Free cash flow-$7.93M-$20.84M-$8.34M$88.9K
Cash & equivalents$4.31M$4.26M$90.0K$345.1K
Total assets$7.45M$16.32M$59.87M$31.00M
Total liabilities$4.57M$12.33M$56.36M$8.26M
Shareholders' equity$3.21M$4.00M$3.51M$22.74M
Return on year-end equity-316.6%-560.2%-420.3%-14.0%
Shares outstanding4.57M138.68M8.97M15.52M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearEnsysce Biosciences, Inc.Cerenome, Inc.ProPhase Labs, Inc.China Pharma Holdings, Inc.
Latest$5.07M
Ended 2025-12-31
$5.21M
Ended 2025-12-31
$4.34M
Ended 2025-12-31
$4.14M
Ended 2025-12-31
1 year earlier$5.21M
Ended 2024-12-31
$5.82M
Ended 2024-12-31
$6.77M
Ended 2024-12-31
$4.53M
Ended 2024-12-31
2 years earlier$2.23M
Ended 2023-12-31
$4.91M
Ended 2023-12-31
$34.98M
Ended 2023-12-31
$7.01M
Ended 2023-12-31
3 years earlier$2.52M
Ended 2022-12-31
n/a$122.65M
Ended 2022-12-31
$8.10M
Ended 2022-12-31
4 years earlier$3.53M
Ended 2021-12-31
n/a$79.04M
Ended 2021-12-31
$9.64M
Ended 2021-12-31